Design Therapeutics, Inc. (DSGN)
15.11
-0.14
(-0.92%)
USD |
NASDAQ |
Aug 28, 16:00
15.09
-0.02
(-0.13%)
After-Hours: 20:00
Design Therapeutics Debt to Equity Ratio : 0.0132 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0132 |
| March 31, 2026 | 0.0125 |
| December 31, 2025 | 0.0072 |
| September 30, 2025 | 0.0087 |
| June 30, 2025 | 0.0091 |
| March 31, 2025 | 0.0094 |
| December 31, 2024 | 0.0096 |
| September 30, 2024 | 0.01 |
| June 30, 2024 | 0.0103 |
| March 31, 2024 | 0.0107 |
| December 31, 2023 | 0.011 |
| Date | Value |
|---|---|
| September 30, 2023 | 0.0113 |
| June 30, 2023 | 0.0114 |
| March 31, 2023 | 0.0113 |
| December 31, 2022 | 0.0113 |
| September 30, 2022 | 0.0113 |
| June 30, 2022 | 0.0112 |
| March 31, 2022 | 0.0095 |
| December 31, 2021 | 0.0095 |
| September 30, 2021 | 0.0096 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Amgen, Inc. | 4.903 |
| AnaptysBio, Inc. | 21.76 |
| 4D Molecular Therapeutics, Inc. | 0.0962 |
| Inhibrx Biosciences, Inc. | -3.428 |
| Agenus, Inc. | -1.458 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 215.13M |
| Total Liabilities (Quarterly) | 13.27M |
| Shareholders Equity (Quarterly) | 201.86M |
| Current Ratio | 18.86 |
| Net Debt Paydown Yield | -0.01% |